AGENERASE
LOE ApproachingNDAORALCAPSULE
Approved
Apr 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AGENERASE is an oral small-molecule capsule approved in 1999 by GSK for an unknown indication. The mechanism of action and pharmacologic class are not specified in available data.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30%), indicating potential team restructuring and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked jobs reflect the product's late-lifecycle maturity and minimal hiring activity. Working on AGENERASE offers stability in a mature product but limited growth trajectory or promotional opportunity.
Brand ManagerField Sales Representative
Worked on AGENERASE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.